|
ANTIDIABETIC EFFECT OF COMBINED AQUEOUS LEAF EXTRACT OF VERNONIA
AMYGDALINA AND METFORMIN IN RATS
Adikwu Michael U1, Uzuegbu David B1,
Okoye Theophine C2*, Uzor Philip F3, Adibe Maxwell
Ogochukwu4*, and Amadi Benson V1
1Department of Pharmaceutics, Faculty of Pharmaceutical
Sciences, University of Nigeria, Nsukka 410001, Enugu State, Nigeria
2Department of Pharmacology and Toxicology, Faculty of Pharmaceutical
Sciences, University of Nigeria, Nsukka 410001, Enugu State, Nigeria
3Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical
Sciences, University of Nigeria, Nsukka 410001, Enugu State,Nigeria
4Department of clinical Pharmacy and Pharmacy Management, Faculty of
Pharmaceutical Sciences, University of Nigeria, 410001, Nsukka, Enugu State, Nigeria
|
Date of Web Publication
|
15-Aug-2010
|
*Corresponding Authors: E-mail: maxolpharmacia@yahoo.com,
theokubs@yahoo.com
ABSTRACT
|
|
|
This study investigated the antidiabetic activity of the various combinations (ratios)
of metformin (50 mg/kg) and aqueous extracts of the leaves of Vernonia amygdalina
(100 mg/kg). The ratios of Extract to Metformin were 1: 1, 2: 1, and 2: 1 and distilled
water (control, p.o.) were given to both normoglycemic and alloxan-induced diabetic
Wister albino rats. Blood was withdrawn and tested at 0, 1, 3 and 6 hours. Results
showed that the combinations of the extract and metformin caused more reduction
in glycemia compared to any of the agents acting alone in either of the two categories
of animals. The ratio of 1:2 caused the most significant (p<0.05) reduction in
blood sugar (-66.07%) compared to distilled water (-7.2%). However,
the ratio of metformin: extract (2: 1) caused a reduction of -62.66% but
was found a better combination considering the safety of the drugs. The combination
of Vernonia amygdalina with metformin for the management of diabetes should
be highly encouraged with a reduction in the dose of metformin and an increase in
the dose of the plant extract to guarantee efficacy and safety.
KEYWORDS: Antidiabetic drug, fasting blood sugar, Metformin, Vernonia amygdalina
INTRODUCTION
|
|
|
Diabetes mellitus is a syndrome of impaired carbohydrate, fat and protein metabolism
caused by either lack of insulin secretion or decreased sensitivity of the tissues
to insulin [1]. It is a metabolic disease
with severe socio-economic importance characterized by hyperglycemia and glycosuria
due to absolute or relative lack of insulin [2].
On the basis of laboratory findings, World Health Organization (WHO) has defined
diabetes mellitus as a fasting venous plasma glucose concentration greater than
7.8mmol/l (140mg/dl) or greater than 11.1 mmol/l (200mg/dl) two hours after a carbohydrate
meal or two hours after an oral ingestion of the equivalent of 75g glucose, even
if the fasting concentration is normal [3].
Recent epidemiological studies indicate that the total number of patients affected
by diabetes in 2004 was close to 190 million, a figure likely to have reached 325
million (an increase of more than 70%) by 2005 [4].
The figures show that the disease is a global health concern that requires serious
effort by all nations towards arresting its scourge. Diabetes is a chronic, incurable
disease; therefore treatment is usually directed towards the relief of the depressing
symptoms such as hyperglycemia and glycosuria [5].
Conventionally, the management protocol of the disease involves non-pharmacological
(diet, exercise and surgery) and/or pharmacological means (insulin and oral hypoglycemic
agents). The conventional medical approach of simply using insulin and oral drugs
to control diabetes mellitus is not only costly but inadequate, boring and associated
with a lot of health risks and complications and these lead to lack of compliance
[6,7].
In response to this, the World Health Assembly, in 1989, adopted among its resolutions,
the support of national traditional medicine program, drawing attention to herbal
medicines as being of great importance to the health of individuals and communities
[8]. Plants extracts have been used for
a long time as a traditional remedy for diabetes in many parts of the world. Many
of them have been investigated. For instance, blueberry leaf extract (mystillin),
extract of periwinkle mistletoe [9] were
investigated and found to possess antidiabetic properties. In Africa, several plants
have been screened based on their usage by the traditional healers for the treatment
of diabetes. Such plants include Anacadium occidental, Piclirima netida, Bridelia
ferugina, Ginburia alypua, Vernonia amygdalina [10].
Some of them have been found to lower glycemia in both normal and chemical-induced
diabetes. Vernonia amygdalina Del. (Astereaceae) popularly known as bitter
leaf is widely used for its therapeutic and nutritional purposes. It is a shrub
of 2–5 m tall with petiolate leaves of about 6.0mm wide [11]. It is native to the South Eastern part of Nigeria where
it is commonly used for preparing soup and has been widely used in folk medicine
as anti-malaria, purgative, antiparasitic, treatment of eczema and for maintaining
healthy blood glucose levels [3]. Other
effects reported for the plant include anthelminthic, antitumorigenic [12,13],
fever, hiccups, and gastric discomfort [14].
Hence the pharmacodynamic properties of V. amygdalina especially its hypoglycemic
activities [15] have received a lot
of research attention in recent years. Also V. amygdalina leaf possesses
both hypoglycemic and hypolipidemic effect and is capable of normalizing other biochemical
and hematological abnormalities associated with diabetes mellitus and thus could
be prescribed as adjunct to dietary and main therapy for diabetes mellitus [16]. The fact that the plant possesses antidiabetic
properties and is also commonly used for edible purpose suggests possibility of
therapeutic interaction when used together with a conventional antidiabetic agent
either consciously or inadvertently. The interaction may be additive, synergistic
or antagonistic. There is need, therefore, to carry out a systematic investigation
into the effect of such combinations. This investigation was aimed at determining
the antidiabetic effect of a combination of the extract from the leaves of Vernonia
amygdalina with an oral hypoglycemic agent, metformin, which belongs to
the class of biguanides as well as the combination ratio that was most appropriate
for hyperglycemic control.
METHODS
|
|
|
Plant Materials
The fresh leaves of V. amygdalina Del. were collected from the natural habitat
in Nsukka, Enugu state, Nigeria in the month of November, 2008. Their botanical
identity was confirmed by Mr. Ogboso of the Department of Pharmacognosy, University
of Nigeria, Nsukka. A voucher specimen of the plant has been deposited in the University
of Nigeria, Nsukka.
Preparation of Extract
The leaves were sorted out to obtain only the fresh leaves and washed with distilled
water without squeezing to remove debris and dust particles. They were shade dried
for three days and dried leaves pulverized with a manual blender. A portion (200
g) of the powdered leaves was cold macerated with distilled water for 24 hours and
filtered to obtain the V. amygdalina aqueous extract (VAE) which was concentrated
in a freeze dryer and stored for screening tests. The appropriate concentrations
of the VAE (43g), referred to as the extract, was made in distilled water for the
experiments.
Chemicals
Metformin (Merk) was purchased from a registered Pharmacy shop, Phymex Pharmacy
Ltd., Minna, Nigeria. The tablets were crushed into powder and appropriate concentrations
of it made in distilled water preparatory to administration to the experimental
animals. Another material used was alloxan monohydrate (Sigma, St Louis MO, USA)
for induction of diabetes in the rats.
Animals
Adult (aged 3–4 months) Wister albino rats weighing 65–200g of either
sex were purchased from the disease-free stock of the animal house of the Faculty
of Veterinary Medicine, University of Nigeria, Nsukka and used for this study. They
were maintained in normal and standard laboratory conditions of temperature (28±2
oC) and relative humidity (46±6%) with 12-hour light-dark
cycle and adequate ventilation. The animals were fed with commercial diet (Vital
Feed Nig. Ltd.) and water, ad libitium. Food was withheld 12 hours before
the experiments, but there was free access to water. Permission for the use of animals
and animal protocols was obtained from the Animal Ethics Committee of the University
of Nigeria, Nsukka, prior to experimentation.
Animal categorization
The animals were allowed 14-day acclimatization period, after which they were randomly
divided into two broad categories: non diabetic (normoglycemic) and diabetic (hyperglycemic)
rats. For the former category, the blood glucose level was confirmed using glucometer
(One-Touch) to determine the sugar level by withdrawing blood from the tail end
and testing. Those with glucose level of 19–39 mg/dL were confirmed to be
in the normoglycemic category and used for the study.
Induction of Diabetes
Diabetes was induced on the latter category by intra- peritoneal injection of 150mg/kg
body weight of alloxan monohydrate freshly prepared with distilled water as the
vehicle. Diabetes was confirmed three days later in alloxan-induced animals showing
Random Blood Glucose (RBG) level ≥ 200 mg/dL by using glucometer to monitor
the blood sample from the tail vein.
Animal grouping and experimental design
The normoglycemic category:
Twenty four rats included in this category were divided into six groups each consisting
of four animals. The various substances were administered as follows:
Group A: 100 mg/kg VAE
Group B: 50 mg/kg metformin,
Group C: VAE + metform (1:1)
Group D: VAE + metformin (2:1)
Group E: VAE+ metformin (1:2)
Group F: distilled water (control).
The hyperglycemic category: Twenty four rats included in this category were divided
into six groups consisting of four animals each. The substances were administered
similar to the normoglycemic category as follows:
Group G: 80 mg/kg VAE
Group H: 40 mg/kg metformin,
Group I: VAE+ metform (1:1)
Group J: VAE+ metformin (2:1)
Group K: VAE + metformin (1:2)
Group L: distilled water (control).
The administration of both the extract and drug was done by oral route. Blood sample
was withdrawn from the tail vein with the aid of a capillary tube and tested using
the glucometer. It was withdrawn just before oral administration of substances (0
hour) and at 1, 3 and 6 hours in each case. The percentage of glycemia reduction
was calculated at the 6th hour during fasting blood sugar (FBS) monitoring using
the formula:

where Go and Gx were the values of 0-hr and 6-hr FBS respectively (17).
Statistical analysis
The results are presented as mean± SEM. Statistical differences between means
were determined by the student’s t-test and p values less than 0.05 were
considered significant.
RESULTS
|
|
|
Antidiabetic effect of the test substances on normoglycemic and hyperglycemic rats
Figure 1 shows the effect of VAE, metformin and their
various combinations in the mean fasting blood sugar of the non-diabetic rats in
comparison with distilled water. It can be seen that while distilled water maintained
the sugar level to almost the starting value (29.5 mg/dL) throughout the duration
of the monitoring period, the VAE showed significant fluctuation around the starting
value (FBS of 27.75 mg/dL). Metformin alone and the extract —metformin combinations
caused a steady and significant reduction in the glycemia in the first five hours.
However, after this period they all showed slight increment in the blood sugar level
of the animals causing an insignificant overall change in glycemia at the 6th hour,
as shown in Table 1. From the table, only the combination
of extract and metformin in 1:1 (group C) and 2:1 (group D) exhibited significant
(p<0.05) reduction in FBS with that of group C being higher (-38%) as
against distilled water (-9.32%), metformin alone (-8.77%) and extract
alone (+0.9%).
In figure 2 which shows the effect of the various substances
on the FBS of the diabetic rats, it can be noticed that all the test substances
(groups G-K) caused steady and significant hypoglycemia during the monitoring period.
Distill water (group L) did not cause significant changes in the glycemia of the
animals. The overall percent changes present this point clearer (Table
1). It shows that the reduction in the FBS caused by the extract and metformin
in any combination is better than that caused by any of them separately though the
combination of 1:2 (group J) caused the highest reduction in FBS (-66.07%)
compare to distilled water (-7.2%), metformin alone (-55.66%) and
extract alone (-55.69%).
DISCUSSION
|
|
|
The effect of the VAE on rats’ blood glucose has implications on its use
for nutritional and therapeutic purposes. The observation that the extract did not
significantly cause a change in the glucose level of the normoglycemic rats after
six hours implies that the extract is safe and does not cause hypoglycemia in a
normal subject taking it either as food or for other medical purposes. Apart from
its safety in normoglycemic individuals, the extract has a high therapeutic index
as the acute toxicity test in rats gave an LD50 of about 1265 mg/kg [8]. In addition, the efficacy of the extract on
hyperglycemic rats corroborates the result of other researchers, who had systematically
demonstrated that the extract from the plant possesses antidiabetic properties [15,
18]. The activity of the extract is attributable to the phytoconstituents.
Compounds such as steroid, glycoside and sesquiterpene lactones like vernodalin
have been isolated from the plant [19].
Nutritionally, it has been demonstrated that the plant contains moisture and fiber
which contribute less sugar to the blood sugar content [6] as plants rich in non starch polysaccharides were reported
to reduce postprandial blood glucose concentrations in humans [20]. Other findings have shown that fiber rich food does not
raise blood glucose [21, 22] rather it enhances insulin sensitivity and
may have a role in the prevention and management of type 2 diabetes [23]. The hypoglycemic effect of the combined agents
suggests that their antidiabetic activities are addictive and this could mean that
the extract and metformin are acting through the same mechanism. According to Shlafer
[24], the current proposed mechanism
of action of metformin include: direct stimulation of glycolysis in tissues with
increase glucose removal from blood; reduced hepatic and renal gluconeogenesis;
slowing of glucose absorption from the gastrointestinal tract with increased glucose
to lactate conversion by enterocytes; and reduction of plasma glucagon levels. Also
its ability to lower glucose levels does not depend on the active pancreatic β-cells
[25] unlike other oral agents such
as the sulphonylureas. This may explain why metformin alone and in combination significantly
reduced the blood sugar in the alloxan-induced diabetic rats as alloxan is a known
β-cytotoxic agent [26]. The
observation that the VAE alone reduced the glycemia significantly in the alloxan
treated rats lends credence that it has peripheral action similar to metformin.
Other workers in this area have also noted that VAE could have a direct insulin-like
effect on glucose metabolism [27, 28].
Furthermore, this observed additive effect has a great clinical implication. There
is need for collaboration between the traditional medicine and the orthodox medical
practitioners in the management of diabetes mellitus. A diabetic patient can be
placed on a reduced dose of metformin (which also implies lower adverse effect)
while being encouraged to consume more of bitter leaf V.amygdalina either
in soup, as commonly used by the populace, or in form of extract. Therefore, V. amydalina
can play a significant role in the management of either insulin dependent or non
insulin dependent diabetes. This is obvious as it is commonly used as diet, which
is known to play a central role in diabetic management [29].
The issue of drug-drug interaction should be seriously considered while a patient
is combining a potent antidiabetic agent and herb remedies. Adibe M.O et al [30] remarked that cautions should be observed
by patients with chronic diseases while using Aloe vera as this may bring
about grievous drug- drug interactions and fatal hypersensitivity. The consequences
are not different in a diabetic patient combining a potent antidiabetic agent and
herbs as this might cause severe hypoglycemia which could lead to coma and ultimately
to death.
In a particular patient, medical practitioners should be aware of potential interactions
and liaise with appropriate authority or drug advisory department to avoid adverse
events which the patient might encounter in course of combining these drugs. Physicians
need to specifically ask patients about traditional medicine use and document this
appropriately and this should be discussed with the patient in an open non-judgemental
manner. Implementation of pharmaceutical care in community pharmacies could help
to alleviate this problem. Community pharmacists can play and active role in the
provision of advisory and educational services to these patients [31].
CONCLUSION
|
|
|
This investigation has demonstrated that the use of a combination of the extract
from the leaves of V. amygdalina and metformin with a greater part of the
extract and reduced dose of metformin is quite efficacious, additive and safe for
the management of diabetes mellitus. The need for collaboration between the orthodox
and herbal practitioners is advocated and increase intake of the leaves of V. amygdalina
by both normal and diabetic patients is encouraged.
REFERENCES
|
|
|
|
|
|
1.
|
Guyton AC. Textbook of Medical Physiology. W.B. Sanders Co, London. 1999: 915–928.
|
|
2.
|
Aguwa CN. Therapeutic Basis for Clinical Pharmacy in the Tropics. Third edn. SNAAP
Press Ltd, Enugu. 2004: 1–230
|
|
3.
|
Nwanjo HU, Nwokoro EA. Antidiabetic and biochemical effects of aqueous extract of
Vernonia amygdalina leaf in normoglycaemic and diabetic rats. J Innov Life
Sci. 2004; 7: 6 –10.
|
|
4.
|
Lefebvre P. Endocrine diseases and diabetes mellitus. Diabetes. 2005; 22: 25–35.
|
|
5.
|
Milton JB. Diabetes: The new approach. Grosset and Duniap Publishers, New York.
1976: 15–17.
|
|
6.
|
Okolie UV, Okeke CE, Oli JM, et al. Hypoglycemic indices of Vernonia amygdalina
on postprandial blood glucose concentration of healthy humans. Afr J Biotech. 2008;
7 (24): 4581–4585.
|
|
7.
|
Adeneye AA and Agbaje EO. Pharmacological Evaluation of Oral Hypoglycemic and Antidiabetic
Effects of Fresh Leaves of Ethanol Extract of Morinda lucida Benth in Normal
and Alloxan-Induced Diabetic Rats. Afr. J. Biomed. 2008; 11 (1): 65–71.
|
|
8.
|
Nwanjo HU. Efficacy of aqueous leaf extract of Vernonia amygdalina on plasma
lipoprotein and oxidative status in diabetic rat models. Nig J Physiol Sci. 2005;
20 (1–2): 39–42.
|
|
9.
|
Kupchan SM. Drug discovery science and development in a changing society. American
Chemical Society, Washington D.C. 1971: 6–8.
|
|
10.
|
Ogbuokiri, JE and Ekpechi DL. Anti-hyperglycaemic activity of Vernonia amygdalina
on healthy adult volunteers. Clin Pharm Herbal Med. 1989; 5(3): 18–21.
|
|
11.
|
Ojiako OA and Nwanjo HU. Is Vernonia amygdalina hepatotoxic or hepatoprotective?
Response from biochemical and toxicity studies in rats. Afr J Biotech. 2006; 5(18):
1648–1651.
|
|
12.
|
Abosi OA and Raseroka BH. In vivo antimalarial activity of Vernonia amygdalina.
Brit J Biomed Sci. 2003; 60(2): 89–91.
|
|
13.
|
Izevbigie EB, Bryant JL and Walker L. A novel natural inhibitor of extracellular
signal-regulated kinases and human breast cancer cell growth. Exp Biol Med. 2004;
229 (2): 163–169.
|
|
14.
|
Hamowia AM and Saffaf AM. Pharmacological studies on Vernonia amygdalina
(Del) and Tithonia diversifolia (Gray). Vet Med J Giza. 1994; 2: 91–97
|
|
15.
|
Akah PA and Okafor CI. Hypoglycaemic effect of Vernonia amygdalina (Del)
in experimental rabbits. Plant Med Res. 1992; 1: 6–10
|
|
16.
|
Akah PA, Alemji JA, Salawu OA, et al. Effects of Vernonia amygdalina on Biochemical
and Haematological Parameters in Diabetic Rats. Asian J Med Sci. 2009; 1(3): 108–113
|
|
17.
|
Fuentes O, Arancibis A and Alarcon H. Hypoglycemic activity of Bauhinia candican
in diabetic induced rabbits. Fitoterapis. 2004; 6: 527–532.
|
|
18.
|
Sabu M, and Kuttan R. Antidiabetic activity of medicinal plants and its relationship
with their antioxidant property. J Ethnopharmacol. 1982; 81: 155–160.
|
|
19.
|
Kupchan SM, Richard JH, Aziz K, et al. Active constituents of plants. J Org Chem.
1969; 34 (6): 3903–3907.
|
|
20.
|
Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavailability.
Am J Clin Nutr. 2004; 79: 727–747.
|
|
21.
|
Ylonen K, Saloranta C, Kronberg C, et al. Associations of Dietary Fiber with Glucose
Metabolism in Non diabetic relatives of subjects with Type 2 Diabetes. Diabetes
care. 2003; 26: 1979–1985.
|
|
22.
|
Oli, J, Ikeakor I, Onwuamaeze I. Blood glucose responses to common Nigerian foods.
Trop Geogr Med. 1982; 34: 317–322.
|
|
23.
|
Henry S. Fiber: An All Natural “Medicine” for Type 2 Diabetes? Consumer
Health Interactive, 2004. Available at: http://www.ahealthyme. com
|
|
24.
|
Shlafter M, Marieb NE. The Nurse, Pharmacology and Drug therapy. Addison-Wesley,
California. 1989: 905–930.
|
|
25.
|
Katzung BG. Basic and Clinical Pharmacology. Mc Grawhill, London. 2001: 711–778.
|
|
26.
|
Rerup CC. Drugs Producing Diabetes through Damage to the Insulin Secreting Cells.
Pharmacological Review. 1970.
|
|
27.
|
Taiwo IA, Odeigah PGC and Ogunkanmi LA. The Glycaemic Effects of Vernonia amygdalina
and V. tenoreana with Tolbutamide in Rats and the Implications for the Treatment
of Diabetes Mellitus. J Sci Res Dev. 2009; 11: 122–130.
|
|
28.
|
Sepici A, Gurbuz I, Cevik C, et al. Hypoglycemic effects of myrtle oil in normal
and alloxan - diabetic rabbits. J Ethnopharmacol. 2004; 93: 311– 318
|
|
29.
|
Mann JI. Diet and Diabetes. Diabetologia. 1980; 18: 89–95.
|
|
30.
|
Adibe Maxwell O, Ukwe Chinwe V and Ekwunife Obinna I. Evaluation of therapeutic
uses of Aloe barbadensis miller (aloe vera) plant amongstaff and students in a Nigerian
university. Int. J. Ph. Sci. May-August 2009; 1(1):59–70. Available online
from: www.ijps.info.
|
|
31.
|
Adibe MO. Prevalence of concurrent use of herbal and synthetic medicines among outpatients
in a mission hospital in Nigeria. Int. J. Drug Dev & Res. Sep-Dec 2009; 1(1):
60–66. Available online from: www.ijddr.com.
|

|